N
CERE

Nuveen’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Nuveen’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-138,380
Closed -$5.66M – 3372
2024
Q2 		$5.66M Sell
138,380
-69,715
-34% -$2.9M ﹤0.01% 1886
2024
Q1 		$8.8M Sell
208,095
-2,386
-1% -$100K ﹤0.01% 1672
2023
Q4 		$8.92M Buy
210,481
+61,871
+42% +$1.78M ﹤0.01% 1660
2023
Q3 		$3.24M Sell
148,610
-1,106
-0.7% -$27.7K ﹤0.01% 2077
2023
Q2 		$4.76M Buy
149,716
+6,810
+5% +$209K ﹤0.01% 1944
2023
Q1 		$3.48M Sell
142,906
-3,062
-2% -$89.9K ﹤0.01% 2085
2022
Q4 		$4.6M Sell
145,968
-3,443
-2% -$97.2K ﹤0.01% 1958
2022
Q3 		$4.22M Sell
149,411
-69,334
-32% -$2.06M ﹤0.01% 1999
2022
Q2 		$5.78M Buy
218,745
+47,690
+28% +$1.35M ﹤0.01% 1855
2022
Q1 		$5.3M Buy
171,055
+3,357
+2% +$98K ﹤0.01% 2028
2021
Q4 		$5.44M Sell
167,698
-28,285
-14% -$998K ﹤0.01% 2069
2021
Q3 		$5.78M Buy
195,983
+46,332
+31% +$1.3M ﹤0.01% 2124
2021
Q2 		$3.83M Buy
+149,651
New +$2.14M ﹤0.01% 2381

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Nuveen's CERE Position: Q3 2024 in Review

Nuveen sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 138,380 shares — an estimated $5.66M sold.

Nuveen first reported a position in CERE in Q2 2021 and held it in 13 quarters. The position peaked at $8.92M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Nuveen reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Nuveen sold 138,380 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $5.66M.
  • Nuveen first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 13 quarters.
  • Nuveen's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $8.92M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Nuveen's 13F filing for Q3 2024, filed 14 Nov 2024.